Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) Equity Average (2019 - 2025)

Avidity Biosciences' Equity Average history spans 7 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Equity Average rose 22.08% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, up 22.08%, while the annual FY2025 figure was $1.6 billion, 61.68% up from the prior year.
  • Equity Average reached $1.8 billion in Q4 2025 per RNA's latest filing, up from $1.5 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.8 billion in Q4 2025 to a low of $275.3 million in Q2 2021.
  • Average Equity Average over 5 years is $777.7 million, with a median of $548.7 million recorded in 2023.
  • The largest YoY upside for Equity Average was 534.52% in 2021 against a maximum downside of 1.37% in 2021.
  • A 5-year view of Equity Average shows it stood at $388.2 million in 2021, then increased by 23.03% to $477.5 million in 2022, then grew by 6.61% to $509.1 million in 2023, then surged by 187.59% to $1.5 billion in 2024, then increased by 22.08% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Equity Average are $1.8 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.3 billion (Q2 2025).